“We started new relationships in New York with Bristol-Myers Squibb, Verastem, AstraZeneca, and Intarcia. “It was a big year for us in adding new clients to our mix,” says CDM New York President Chris Palmer. In 2017, CDM marked change by expanding its client base, achieving new heights of creative recognition, and continuing to drive innovative work on behalf of its clients, executives say. And we’re doing it now when we partner with our clients to help change despair into hope for people living with rare diseases or cancer.” “We did it 20 years ago when we helped change ‘impotence’ to ‘E.D.’. “CDM exists to make meaningful changes in healthcare,” Barich says. We seek to be a lifechanging agency for our people, for our clients, for our brands, and ultimately, for people impacted by disease.”įundamental to this vision for the agency is the idea of embracing – and propelling – change. “Great companies are driven by a purpose, by uncovering the ‘why’ behind their business,” says CEO Kyle Barich. CDM enacted a bold new vision for the agency, made important changes in leadership, implemented a new global strategy, and – most important, agency leaders say – delivered enormous results for clients.
According to CDM executives, 2017 was a year in which one of the biggest agency brands in healthcare made some big moves.